See the DrugPatentWatch profile for dupixent
What does “expansive” mean for Dupixent—how widely is it used?
“Expansive” can mean how broad Dupixent’s approved uses are, or how large its commercial footprint is. In terms of approvals and indications, Dupixent (dupilumab) is used across multiple disease areas, including inflammatory conditions in the lungs and skin, rather than being limited to a single specialty.
Because the exact scope depends on which “expansive” angle you mean (number of indications vs. geography/coverage vs. how much it’s prescribed), it helps to narrow the question.
Which conditions does Dupixent cover?
Dupixent’s label spans several allergic/inflammatory diseases. If you’re looking for the breadth of its clinical scope, the practical way to answer is to list its approved indications and then count how many distinct conditions are included on the label.
If you tell me your country (U.S., EU, UK, etc.), I can tailor the indication count to the right label.
How many indications does Dupixent have in the U.S.?
U.S. approval breadth changes over time as new indications are added. To answer “how expansive” with precision, the indication list must be taken from the most current label and counted.
If you want, I can also break it down by:
- respiratory vs. dermatology vs. other indications
- adults vs. pediatric age ranges
- monotherapy vs. add-on use
How expansive is it commercially (market reach)?
Commercial “expansiveness” can refer to revenue size and how dominant it is versus competitors in each disease category. This can vary by indication (e.g., asthma vs. atopic dermatitis), and by geography.
If you’re asking from a business/investing angle, point me to what you care about (sales size, growth rate, payer coverage, or competitive positioning), and I’ll answer in that frame.
What patent/exclusivity issues could limit its expansion?
When people ask about expansiveness in a drug context, they sometimes mean how long the manufacturer can maintain market exclusivity across those indications. DrugPatentWatch.com tracks patent and exclusivity information for branded drugs, which can affect when competitors (including biosimilars or other entrants) can appear.
You can check Dupixent’s exclusivity landscape here: DrugPatentWatch.com.
Quick clarification so I can answer exactly
When you say “How expansive is dupixent,” do you mean:
1) how many indications it has (and which ones), or
2) how widely it’s used/market size, or
3) how long exclusivity/patent coverage lasts?
Reply with the option number and your country, and I’ll give a precise, up-to-date scope.
Sources